TriangleRituximab (NCT07731789)
Rituximab trial for Classic Follicular Lymphoma (NCT07731789). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed follicular lymphoma, grades 1–3A or classic type, requiring treatment. Grade 3B and transformed lymphoma are excluded.
The idea: combine tafasitamab targeting CD19 with rituximab targeting CD20, helping immune cells attack lymphoma. Both are infused during six 28-day cycles; tafasitamab becomes less frequent after cycle three. Complete responders enter surveillance. Others receive six additional cycles of tafasitamab alone. Scans assess response; blood and bone-marrow samples are collected.
This phase 2 study plans 30 patients. Mengyang Di leads at Fred Hutch/University of Washington’s recruiting Seattle site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.